Avid Bioservices Inc (CDMO)

[biopharm]

Looks like Eli Lilly has some bigger backers than some thought, and Danaher needs help with those GE IP assets they are spending on.

Midcap Financial backers of Biothera as well and were they not the ones showing up new on some IP assets held by Peregrine last year....hmmmm

Danaher not updating shareholders till March 14

Lots of puzzle pieces coming back to life with CALICO / QB3 / Tracy Saxton / Pivotal Bioventure Partners and much more...

What were the new BODs promised? What made it all such a big secret that they had to create Oncologie within 30 days of PR

I guess some that were left out of the deal still have a little float left to try and pick up some shares, if possible ...

Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.
Fischl AS, et al. Mol Cancer Ther. 2019.
Authors
Fischl AS1, Wang X2, Falcon BL3, Almonte-Baldonado R4, Bodenmiller D1, Evans G1, Stewart J5, Wilson T3, Hipskind P1, Manro JR6, Uhlik MT7, Chintharlapalli S3, Gerald D3, Alsop DC8, Benjamin LE9, Bhatt RS10.
Author information
1
Eli Lilly and Company.
2
Department of Medical Oncology, Dana-Farber Cancer Institute.
3
Oncology Research, Eli Lilly and Company.
4
Cancer Research, Eli Lilly and Company.
5
Oncology Translational Research, Eli Lilly.
6
Discovery Statistics, Eli Lilly and Company.
7
Translational Oncology, Biothera Pharmaceuticals, Inc.
8
Department of Radiology, Ansin 226, Beth Israel Deaconess Medical Center.
9
Oncology, KatahdinRX.
10
Division of Hematology-Oncology, Beth Israel Deaconess Medical Center [e-mail].
Citation
Mol Cancer Ther. 2019 Feb 20. pii: molcanther.0548.2018. doi: 10.1158/1535-7163.MCT-18-0548. [Epub ahead of print]
Abstract
Inhibition of vascular endothelial growth factor receptor (VEGFR) signaling is an effective treatment for renal cell carcinoma but resistance continues to be a major problem. Recently, the sphingosine phosphate (S1P) signaling pathway has been implicated in tumor growth, angiogenesis and resistance to antiangiogenic therapy. S1P is a bioactive lipid that serves an essential role in developmental and pathological angiogenesis via activation of the S1P receptor 1 (S1P1). S1P1 signaling counteracts VEGF signaling and is required for vascular stabilization. We used in vivo and in vitro angiogenesis models including a post-natal retinal angiogenesis model and a renal cell carcinoma murine tumor model to test whether simultaneous inhibition of S1P1 and VEGF leads to improved angiogenic inhibition. Here we show that inhibition of S1P signaling reduces the endothelial cell barrier and leads to excessive angiogenic sprouting. Simultaneous inhibition of S1P and VEGF signaling further-disrupts the tumor vascular beds, decreases tumor volume, and increases tumor cell death compared to monotherapies. These studies suggest that inhibition of angiogenesis at two stages of the multi-step process may maximize the effects of antiangiogenic therapy. Together these data suggest that combination S1P1 and VEGFR targeted therapy may be a useful therapeutic strategy for the treatment of renal cell carcinoma and other tumor types.

Copyright ©2019, American Association for Cancer Research.
PMID 30787172 [ - as supplied by publisher]